Journals / Neurological sciences and neurophysiology (Online) / 2020 / Cilt: 37 - Sayı: 2

The Role of Leukoaraiosis on Outcomes and Recombinant Tissue-plasminogen Activator-related Symptomatic Intracerebral Hemorrhages in Acute Stroke

Pages
70–74
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall sICH rate was 3.6%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Purpose: We aimed to assess whether severe leukoaraiosis (LA) is associated with outcomes and symptomatic intracerebral hemorrhages (sICH) in patients who were treated with recombinant tissue‑plasminogen activator (rt‑PA) for acute stroke.
📊
Key Findings & Data:Methods: We analyzed the data of anterior circulation stroke patients who were treated with rt‑PA at our stroke center during 2009–2016.
💡
Conclusion & Impact:The overall sICH rate was 3.6%.
🔬Design:Research Article
📍Scope:2009–2016 Verileri
⚙️Variables:Domain Parameters

Özet

Background and Purpose: We aimed to assess whether severe leukoaraiosis (LA) is associated with outcomes and symptomatic intracerebral hemorrhages (sICH) in patients who were treated with recombinant tissue‑plasminogen activator (rt‑PA) for acute stroke. Methods: We analyzed the data of anterior circulation stroke patients who were treated with rt‑PA at our stroke center during 2009–2016. LA was scored according to the van Swieten scale (VSS) on computed tomography (CT) and dichotomized into groups as absent or moderate versus severe LA. We used the safe implementation of thrombolysis in stroke definition for sICH and the modified Rankin Scale (mRS) scores at 3 months after rt‑PA were recorded. Results: Of 302 patients, 47 (15.6%) showed severe LA (VSS >4) on CT. The overall sICH rate was 3.6%. Moreover, sICH was significantly more frequent in patients with severe LA (n = 5 of 47; 10.6%) than in patients with absent/moderate LA (n = 6 of 255; 2.4%; P = 0.017). In addition, patients with severe LA had higher baseline glucose level (P = 0.006) and systolic blood pressure (P = 0.005) compared to patients with absent/moderate LA. Patients with severe LA were more likely to have a poor outcome (mRS: 3–6) compared to those without severe LA (P = 0.009). Conclusion: The presence of severe LA on CT increases the risk of sICH and poor outcome in patients treated with rt‑PA for acute stroke.

🔖

Cite This Article

ERYILDIZ, E. S., ÖZDEMİR, A. Ö., YILMAZ, D. Ç., BAŞ, D. F. (2020). The Role of Leukoaraiosis on Outcomes and Recombinant Tissue-plasminogen Activator-related Symptomatic Intracerebral Hemorrhages in Acute Stroke. Neurological sciences and neurophysiology (Online), Cilt: 37 - Sayı: 2, 70–74. https://ajindex.com/articles/290611

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Tanne D, Kasner SE, Demchuk AM, Koren‑Morag N, Hanson S, Grond M, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The multicenter rt‑PA stroke survey. Circulation 2002;105:1679‑85. 2. von Kummer R, Allen KL, Holle R, Bozzao L, Bastianello S, Manelfe C, et al. Acute stroke: Usefulness of early CT findings before thrombolytic therapy. Radiology 1997;205:327‑33
  2. Hachinski VC, Potter P, Merskey H. Leuko‑araiosis. Arch Neurol 1987;44:21‑3
  3. Tveiten A, Ljøstad U, Mygland A, Naess H. Leukoaraiosis is associated with short‑ and long‑term mortality in patients with ıntracerebral hemorrhage. J Stroke Cerebrovasc Dis 2013;22:919‑25
  4. Selekler K, Erzen C. Leukoaraiosis and intracerebral hematoma. Stroke 1989;20:1016‑20
  5. Inzitari D, Giordano GP, Ancona AL, Pracucci G, Mascalchi M, Amaducci L. Leukoaraiosis, intracerebral hemorrhage, and arterial hypertension. Stroke 1990;21:1419‑23
  6. Kato H, Izumiyama M, Izumiyama K, Takahashi A, Itoyama Y. Silent cerebral microbleeds on T2‑weighted MRI: Correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke 2002;33:1536‑40
  7. Lee SH, Bae HJ, Kwon SJ, Kim H, Kim YH, Yoon BW, et al. Cerebral microbleeds are regionally associated with intracerebral hemorrhage. Neurology 2004;62:72‑6
  8. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457‑507
  9. Larrue V, von Kummer R R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European‑Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438‑41
  10. Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012;43:1524‑31. 12. van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: A simple scale. J Neurol Neurosurg Psychiatry 1990;53:1080‑3
  11. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Stroke prevention ın reversible ıschemia trial (SPI